{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T05:21:03Z","timestamp":1740028863386,"version":"3.37.3"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1124\/jpet.106.105395","type":"journal-article","created":{"date-parts":[[2006,6,27]],"date-time":"2006-06-27T00:52:44Z","timestamp":1151369564000},"page":"247-253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Separation of Binding Affinity and Intrinsic Activity of the Potent \u03bc-Opioid 14-Methoxymetopon"],"prefix":"10.1016","volume":"319","author":[{"given":"Loriann","family":"Mahurter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"Garceau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Marino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Schmidhammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9za","family":"T\u00f3th","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavril W.","family":"Pasternak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"doi-asserted-by":"crossref","unstructured":"Bare LA, Mansson E, and Yang D (1994) Expression of two variants of the human m opioid receptor mRNA in SK-N-SH cells and human brain. FEBS Lett 354: 213-216.","key":"10.1124\/jpet.106.105395_bib1","DOI":"10.1016\/0014-5793(94)01129-X"},{"doi-asserted-by":"crossref","unstructured":"Bileviciute-Ljungar I, Spetea M, Guo Y, Schutz J, Windisch P, and Schmidhammer H (2006) Peripherally mediated antinociception of the \u03bc-opioid receptor agonist 2-[(4,5\u03b1-epoxy-3-hydroxy-14\u03b2-methoxy-17-methylmorphinan-6\u03b2-yl) amino]acetic acid (HS-731) after subcutaneous and oral administration in rats with carrageenan-induced hindpaw inflammation. J Pharmacol Exp Ther 317: 220-227.","key":"10.1124\/jpet.106.105395_bib2","DOI":"10.1124\/jpet.105.096032"},{"doi-asserted-by":"crossref","unstructured":"Bolan EA, Pasternak GW, and Pan Y-X (2004) Functional analysis of MOR-1 splice variants of the mu opioid receptor gene Oprm. Synapse 51: 11-18.","key":"10.1124\/jpet.106.105395_bib3","DOI":"10.1002\/syn.10277"},{"doi-asserted-by":"crossref","unstructured":"Chen Y, Mestek A, Liu J, Hurley JA, and Yu L (1993) Molecular cloning and functional expression of a \u03bc-opioid receptor from rat brain. Mol Pharmacol 44: 8-12.","key":"10.1124\/jpet.106.105395_bib4","DOI":"10.1016\/S0026-895X(25)13175-1"},{"doi-asserted-by":"crossref","unstructured":"Childers SR, Creese I, Snowman AM, and Snyder SH (1979) Opiate receptor binding affected differentially by opiates and opioid peptides. Eur J Pharmacol 55: 11-18.","key":"10.1124\/jpet.106.105395_bib5","DOI":"10.1016\/0014-2999(79)90142-0"},{"doi-asserted-by":"crossref","unstructured":"Childers SR and Snyder SH (1978) Guanine nucleotides differentiate agonist and antagonist interactions with opiate receptors. Life Sci 23: 759-762.","key":"10.1124\/jpet.106.105395_bib6","DOI":"10.1016\/0024-3205(78)90077-2"},{"doi-asserted-by":"crossref","unstructured":"Childers SR and Snyder SH (1980) Differential regulation by guanine nucleotides of opiate agonist and antagonist receptor interactions. J Neurochem 34: 583-593.","key":"10.1124\/jpet.106.105395_bib7","DOI":"10.1111\/j.1471-4159.1980.tb11184.x"},{"doi-asserted-by":"crossref","unstructured":"Creese I, Pasternak GW, Pert CB, and Snyder SH (1975) Discrimination by temperature of opiate agonist and antagonist receptor binding. Life Sci 16: 1837-1842.","key":"10.1124\/jpet.106.105395_bib8","DOI":"10.1016\/0024-3205(75)90287-8"},{"doi-asserted-by":"crossref","unstructured":"Eppler CM, Hulmes JD, Wang JB, Johnson B, Corbett M, Luthin DR, Uhl GR, and Linden J (1993) Purification and partial amino acid sequence of a \u03bc opioid receptor from rat brain. J Biol Chem 268: 26447-26451.","key":"10.1124\/jpet.106.105395_bib9","DOI":"10.1016\/S0021-9258(19)74335-X"},{"doi-asserted-by":"crossref","unstructured":"Freye E, Schmidhammer H, and Latasch L (2000) 14-Methoxymetopon, a potent opioid, induces no respiratory depression, less sedation, and less bradycardia than sufentanil in the dog. Anesth Analg 90: 1359-1364.","key":"10.1124\/jpet.106.105395_bib10","DOI":"10.1097\/00000539-200006000-00018"},{"doi-asserted-by":"crossref","unstructured":"F\u00fcrst Z, Buzas B, Friedmann T, Schmidhammer H, and Borsodi A (1993) Highly potent novel opioid receptor agonist in the 14-alkoxymetopon series. Eur J Pharmacol 236: 209-215.","key":"10.1124\/jpet.106.105395_bib11","DOI":"10.1016\/0014-2999(93)90591-5"},{"doi-asserted-by":"crossref","unstructured":"Hahn EF, Carroll-Buatti M, and Pasternak GW (1982) Irreversible opiate agonists and antagonists: the 14-hydroxydihydromorphinone azines. J Neurosci 2: 572-576.","key":"10.1124\/jpet.106.105395_bib12","DOI":"10.1523\/JNEUROSCI.02-05-00572.1982"},{"doi-asserted-by":"crossref","unstructured":"Heyman JS, Williams CL, Burks TF, Mosberg HI, and Porreca F (1988) Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine. J Pharmacol Exp Ther 245: 238-243.","key":"10.1124\/jpet.106.105395_bib13","DOI":"10.1016\/S0022-3565(25)22285-6"},{"doi-asserted-by":"crossref","unstructured":"King MA, Su W, Nielan CL, Chang AH, Schutz J, Schmidhammer H, and Pasternak GW (2003) 14-Methoxymetopon, a very potent mu-opioid receptor-selective analgesic with an unusual pharmacological profile. Eur J Pharmacol 459: 203-209.","key":"10.1124\/jpet.106.105395_bib14","DOI":"10.1016\/S0014-2999(02)02821-2"},{"doi-asserted-by":"crossref","unstructured":"Ling GSF, MacLeod JM, Lee S, Lockhart SH, and Pasternak GW (1984) Separation of morphine analgesia from physical dependence. Science (Wash DC) 226: 462-464.","key":"10.1124\/jpet.106.105395_bib15","DOI":"10.1126\/science.6541807"},{"doi-asserted-by":"crossref","unstructured":"Ling GSF, Spiegel K, Lockhart SH, and Pasternak GW (1985) Separation of opioid analgesia from respiratory depression: evidence for different receptor mechanisms. J Pharmacol Exp Ther 232: 149-155.","key":"10.1124\/jpet.106.105395_bib16","DOI":"10.1016\/S0022-3565(25)20062-3"},{"doi-asserted-by":"crossref","unstructured":"Ling GSF, Spiegel K, Nishimura S, and Pasternak GW (1983) Dissociation of morphine\u2019s analgesic and respiratory depressant actions. Eur J Pharmacol 86: 487-488.","key":"10.1124\/jpet.106.105395_bib17","DOI":"10.1016\/0014-2999(83)90203-0"},{"doi-asserted-by":"crossref","unstructured":"Lutz RA, Cruciani RA, Costa T, Munson PJ, and Rodbard D (1984) A very high affinity opioid binding site in rat brain: demonstration by computer modeling. Biochem Biophys Res Commun 122: 265-269.","key":"10.1124\/jpet.106.105395_bib18","DOI":"10.1016\/0006-291X(84)90469-8"},{"doi-asserted-by":"crossref","unstructured":"Pan L, Xu J, Yu R, Xu M, Pan YX, and Pasternak GW (2005a) Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm. Neuroscience 133: 209-220.","key":"10.1124\/jpet.106.105395_bib19","DOI":"10.1016\/j.neuroscience.2004.12.033"},{"doi-asserted-by":"crossref","unstructured":"Pan YX, Xu J, Bolan E, Chang A, Mahurter L, Rossi G, and Pasternak GW (2000) Isolation and expression of a novel alternatively spliced mu opioid receptor isoform, MOR-1F. FEBS Lett 466: 337-340.","key":"10.1124\/jpet.106.105395_bib20","DOI":"10.1016\/S0014-5793(00)01095-4"},{"doi-asserted-by":"crossref","unstructured":"Pan YX, Xu J, Bolan EA, Abbadie C, Chang A, Zuckerman A, Rossi GC, and Pasternak GW (1999) Identification and characterization of three new alternatively spliced mu opioid receptor isoforms. Mol Pharmacol 56: 396-403.","key":"10.1124\/jpet.106.105395_bib21","DOI":"10.1124\/mol.56.2.396"},{"doi-asserted-by":"crossref","unstructured":"Pan YX, Xu J, Bolan E, Moskowitz HS, Xu M, and Pasternak GW (2005b) Identification of four novel exon 5 splice variants of the mouse \u03bc-opioid receptor gene: functional consequences of C-terminal splicing. Mol Pharmacol 68: 866-875.","key":"10.1124\/jpet.106.105395_bib22","DOI":"10.1124\/mol.105.011858"},{"doi-asserted-by":"crossref","unstructured":"Pan YX, Xu J, Mahurter L, Bolan EA, Xu MM, and Pasternak GW (2001) Generation of the mu opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene. Proc Natl Acad Sci USA 98: 14084-14089.","key":"10.1124\/jpet.106.105395_bib23","DOI":"10.1073\/pnas.241296098"},{"doi-asserted-by":"crossref","unstructured":"Pan YX, Xu J, Mahurter L, Xu MM, Gilbert A-K, and Pasternak GW (2003) Identification and characterization of two new human mu opioid receptor splice variants, hMOR-1O and hMOR-1X. Biochem Biophys Res Commun 301: 1057-1061.","key":"10.1124\/jpet.106.105395_bib24","DOI":"10.1016\/S0006-291X(03)00089-5"},{"doi-asserted-by":"crossref","unstructured":"Pasternak DA, Pan L, Xu J, Yu R, Xu M, Pasternak GW, and Pan Y-X (2004) Identification of three new alternatively spliced variants of the rat mu opioid receptor gene: dissociation of affinity and efficacy. J Neurochem 91: 881-890.","key":"10.1124\/jpet.106.105395_bib25","DOI":"10.1111\/j.1471-4159.2004.02767.x"},{"doi-asserted-by":"crossref","unstructured":"Pasternak GW, Childers SR, and Snyder SH (1980a) Naloxazone, long-acting opiate antagonist: effects in intact animals and on opiate receptor binding in vitro. J Pharmacol Exp Ther 214: 455-462.","key":"10.1124\/jpet.106.105395_bib26","DOI":"10.1016\/S0022-3565(25)32200-7"},{"doi-asserted-by":"crossref","unstructured":"Pasternak GW, Childers SR, and Snyder SH (1980b) Opiate analgesia: evidence for mediation by a subpopulation of opiate receptors. Science (Wash DC) 208: 514-516.","key":"10.1124\/jpet.106.105395_bib27","DOI":"10.1126\/science.6245448"},{"doi-asserted-by":"crossref","unstructured":"Pasternak GW, Snowman AS, and Snyder SH (1975) Selective enhancement of [3H]opiate agonist binding by divalent cations. Mol Pharmacol 11: 478-484.","key":"10.1124\/jpet.106.105395_bib28","DOI":"10.1016\/S0026-895X(25)10654-8"},{"doi-asserted-by":"crossref","unstructured":"Paul D and Pasternak GW (1988) Differential blockade by naloxonazine of two m opiate actions: analgesia and inhibition of gastrointestinal transit. Eur J Pharmacol 149: 403-404.","key":"10.1124\/jpet.106.105395_bib29","DOI":"10.1016\/0014-2999(88)90680-2"},{"doi-asserted-by":"crossref","unstructured":"Pert CB, Pasternak GW, and Snyder SH (1973) Opiate agonists and antagonists discriminated by receptor binding in brain. Science (Wash DC) 182: 1359-1361.","key":"10.1124\/jpet.106.105395_bib30","DOI":"10.1126\/science.182.4119.1359"},{"doi-asserted-by":"crossref","unstructured":"Schmidhammer H, Schratz A, and Mitterdorfer J (1990) Synthesis and biological evaluation of the 14-alkoxymorphinans. 8. 14-Methoxymetopon, an extremely potent opioid agonist. Helv Chim Acta 73: 1784-1787.","key":"10.1124\/jpet.106.105395_bib31","DOI":"10.1002\/hlca.19900730623"},{"doi-asserted-by":"crossref","unstructured":"Spetea M, Harris HE, Berzetei-Gurske IP, Klareskog L, and Schmidhammer H (2001) Binding, pharmacological and immunological profiles of the delta-selective opioid receptor antagonist HS 378. Life Sci 69: 1775-1782.","key":"10.1124\/jpet.106.105395_bib32","DOI":"10.1016\/S0024-3205(01)01271-1"},{"doi-asserted-by":"crossref","unstructured":"Spetea M, Toth F, Schutz J, Otvos F, Toth G, Benyhe S, Borsodi A, and Schmidhammer H (2003) Binding characteristics of [3H]14-methoxymetopon, a high affinity mu-opioid receptor agonist. Eur J Neurosci 18: 290-295.","key":"10.1124\/jpet.106.105395_bib33","DOI":"10.1046\/j.1460-9568.2003.02744.x"},{"doi-asserted-by":"crossref","unstructured":"Thompson RC, Mansour A, Akil H, and Watson SJ (1993) Cloning and pharmacological characterization of a rat m opioid receptor. Neuron 11: 903-913.","key":"10.1124\/jpet.106.105395_bib34","DOI":"10.1016\/0896-6273(93)90120-G"},{"doi-asserted-by":"crossref","unstructured":"Wang JB, Imai Y, Eppler CM, Gregor P, Spivak CE, and Uhl GR (1993) mu Opiate receptor: cDNA cloning and expression. Proc Natl Acad Sci USA 90: 10230-10234.","key":"10.1124\/jpet.106.105395_bib35","DOI":"10.1073\/pnas.90.21.10230"},{"doi-asserted-by":"crossref","unstructured":"Wolozin BL and Pasternak GW (1981) Classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc Natl Acad Sci USA 78: 6181-6185.","key":"10.1124\/jpet.106.105395_bib36","DOI":"10.1073\/pnas.78.10.6181"},{"doi-asserted-by":"crossref","unstructured":"Zernig G, Saria A, Krassnig R, and Schmidhammer H (2000) Signal transduction efficacy of the highly potent mu opioid agonist 14-methoxymetopon. Life Sci 66: 1871-1877.","key":"10.1124\/jpet.106.105395_bib37","DOI":"10.1016\/S0024-3205(00)00510-5"},{"doi-asserted-by":"crossref","unstructured":"Zimprich A, Bacher B, and H\u00f6llt V (1994) Cloning and expression of an isoform of the rmu-opioid receptor (rmuOR1B). Regul Pept 54: 347-348.","key":"10.1124\/jpet.106.105395_bib38","DOI":"10.1016\/0167-0115(94)90531-2"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524329477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524329477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.106.105395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T22:01:26Z","timestamp":1740002486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524329477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0022356524329477"],"URL":"https:\/\/doi.org\/10.1124\/jpet.106.105395","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2006,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Separation of Binding Affinity and Intrinsic Activity of the Potent \u03bc-Opioid 14-Methoxymetopon","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.106.105395","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2006 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}